Abstract:BACKGROUND: Plasma circulating tumor DNA (ctDNA) may be a surrogate, minimally invasive approach to tissue-based epidermal growth factor receptor (EGFR) mutation detection in non-small cell lung cancer (NSCLC) patients. However, the predictive ability of preoperative ctDNA EGFR mutation test on long-term postoperative survival and tumor metastasis development has not been extensively investigated.METHODS: Stage I-III NSCLC patients with tissue EGFR mutations were enrolled in this study (n=174). The ctDNA EGFR mutations were identified in paired preoperative plasma samples. EGFR mutation testing was performed using Scorpion amplified refractory mutation system (ARMS) technology. The correlation between ctDNA EGFR mutation status and clinicopathologic parameters was analyzed. By combining at least 5 years of follow-up data, we assessed the relationship between ctDNA EGFR mutation status and disease-free survival (DFS) and overall survival (OS).RESULTS: Plasma-based ctDNA EGFR mutations were detected in 27 patients. The mutation types were exactly matched with those in paired tissue samples. Blood test sensitivity was closely associated with N stages, tumor-node-metastasis (TNM) stages and tumor differentiation (P<0.001). The overall 5-year survival rate was 18.5% versus 76.9% for ctDNA EGFR mutation-positive and ctDNA EGFR mutation-negative patients, respectively. For patients with ctDNA EGFR mutation positive, the median OS and DFS were 29.00±2.55 and 19.00±2.50 months, respectively, which were both significantly better than those in the ctDNA EGFR mutation-negative subgroup (P<0.001). ctDNA EGFR mutation was an independent risk factor of OS and DFS [hazard ratio (HR) 3.289, 95% confidence interval (CI), 1.816-5.956, P<0.001; HR, 4.860, 95% CI, 2.660-8.880, P<0.001]. For stage III patients with exon 19 deletion or L858R mutations in both tissue and plasma samples, tyrosine kinase inhibitor (TKI) therapy showed significantly better OS (P=0.025) and possible DFS benefit (P=0.060) than did chemotherapy.CONCLUSIONS: EGFR mutation testing using the Scorpion-ARMS method in preoperative plasma could be a strong predictor for postoperative survival and metastasis of NSCLC patients. Thus, the subset of this population may be benefit from targeted strategies and management.

Comparison of EGFR Mutations Detected by LNA-ARMS PCR in Plasma Ctdna Samples and Matched Tissue Sample in Non-Small Cell Lung Cancer Patients.

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.

Comparison of Egfr Mutation Status Between Plasma and Tumor Tissue in Non-Small Cell Lung Cancer Using the Scorpion Arms Method and the Possible Prognostic Significance of Plasma Egfr Mutation Status

Egfr Mutation Status In Plasma And Tumor Tissues In Non-Small Cell Lung Cancer Serves As A Predictor Of Response To Egfr-Tki Treatment

Detection of Epidermal Growth Factor Receptor Mutations in Small Specimens of Non-Small Cell Lung Cancer by Amplification Refractory Mutation System

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

Comparison of EGFR mutations in blood and tumor tissue samples by allele-specific PCR

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Ultrasensitive and Quantitative Detection of EGFR Mutations in Plasma Samples from Patients with Non-Small-cell Lung Cancer Using a Dual PNA Clamping-Mediated LNA-PNA PCR Clamp

A Comparison of ARMS and Direct Sequencing for EGFR Mutation Analysis and Tyrosine Kinase Inhibitors Treatment Prediction in Body Fluid Samples of Non-Small-Cell Lung Cancer Patients

Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations

Assessment of EGFR Mutations in Plasma from Advanced NSCLC Patients by Modified Cell-Free DNA Extraction Method and Blocker PCR Assays

Detecting T790M Mutation of Tissue and Plasma Ctdna Samples by ARMS in EGFR-mutant NSCLC Patients after Disease Progression.

Comparison of Different Methods for Detecting Epidermal Growth Factor Receptor Mutations in Peripheral Blood and Tumor Tissue of Non-Small Cell Lung Cancer As A Predictor of Response to Gefitinib

Detection Of' Epidermal Growth Factor Receptor Mutations In Plasma By Mutant-Enriched Pcr Assay For Prediction Of The Response To Gefitinib In Patients With Non-Small-Celi Lung Cancer

A comparison of ARMS-Plus and droplet digital PCR for detecting EGFR activating mutations in plasma

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI

Analysis of Egfr Mutation Status in Tissue and Plasma for Predicting Response to Egfr-Tkis in Advanced Non-Small-Cell Lung Cancer

Comparison of Egfr Signaling Pathway Somatic Dna Mutations Derived from Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology

Cross-Platform Comparison Of Four Leading Technologies For Detecting Egfr Mutations In Circulating Tumor Dna From Plasma Of Patients With Non-Small Cell Lung Carcinoma